I期肺癌立体定向放疗10年以上随访结局评估
该回顾性研究分析了44例接受SBRT的I期肺癌患者,随访超过10年。中位临床随访143个月,出现支气管狭窄/阻塞、胸壁肿块样形成和心包炎等晚期毒性,10年后无局部失败,未发现放疗诱发恶性肿瘤。
要点
- 10年后出现支气管狭窄/阻塞继发感染(5级)、胸壁肿块模拟恶性肿瘤(3级)和心包炎(3级)等非典型晚期毒性。
- 5年后有3例局部失败,但10年后无复发,未发现放疗诱发第二原发恶性肿瘤。
- 19例死亡中仅2例死于肺癌,提示长期随访中需关注非癌死因及晚期毒性。
核心结论
- SBRT治疗I期肺癌后10年以上可观察到标准随访期未见的晚期毒性,但10年后无局部失败且无放疗诱发恶性肿瘤。
研究设计与样本
- 单中心回顾性分析2001至2014年246例接受SBRT的I期肺癌(≤5 cm)患者中44例随访超过10年者,复习临床记录和影像资料评估晚期毒性、复发和第二原发恶性肿瘤。
主要发现
- 中位临床随访143个月(范围120-202),中位影像随访128个月(范围60-199),中位年龄77岁(范围58-86),68%经组织学确诊。
- 处方剂量40-70 Gy分4-10次;末次随访时19例死亡,其中2例死于肺癌、16例死于其他原因、1例死于治疗相关脓胸。
- 10年后出现3种非典型晚期毒性:支气管狭窄/阻塞继发感染(5级)、胸壁肿块模拟恶性肿瘤(3级)、心包炎(3级);1例因第二原发肺癌再程SBRT后间质性肺病急性加重死亡。
- 5例复发,其中3例局部失败发生于5年后,10年后无复发;未发现放疗诱发恶性肿瘤。
临床怎么用
- 对SBRT后长期生存的I期肺癌患者,应延长随访监测以识别10年后可能出现的晚期毒性。
局限性
- 样本量小且存在生存者偏倚,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiotherapy (SBRT) is a well-established treatment for early stage non-small cell lung cancer (NSCLC); however, outcomes beyond 10 years remain poorly defined. We aimed to evaluate late toxicities, recurrence patterns, and secondary malignancies in patients with ≥10 years of follow-up after SBRT. METHODS AND MATERIALS: Among 246 patients treated with SBRT for histologically confirmed NSCLC or clinically diagnosed lung cancer (≤5 cm) between 2001 and 2014 at our institution, 44 patients with follow-up exceeding 10 years were retrospectively analyzed. Clinical records and imaging data, including those from external institutions, were reviewed to assess late toxicity, recurrence, and secondary malignancies. Descriptive analyses focused on long-term survivors. RESULTS: Median clinical and imaging follow-up durations were 143 months (range: 120-202) and 128 months (range: 60-199), respectively. The median patient age was 77 years (range: 58-86), and 68% underwent histological confirmation. Prescribed doses ranged from 40-70 Gy delivered in 4-10 fractions. At the last follow-up, 19 patients had died: 2 from lung cancer, 16 from other causes, and 1 from treatment-related empyema. The following three atypical late toxicities emerged beyond 10 years: bronchial stenosis/obstruction with secondary infection (grade 5), chest wall mass formation simulating malignancy (grade 3), and pericardial inflammation (grade 3). One patient died from an acute exacerbation of interstitial lung disease following repeat SBRT for a second primary lung cancer. Recurrence occurred in five patients, including three local failures observed beyond 5 years; no recurrences occurred after 10 years. No radiation-induced malignancies were identified. CONCLUSIONS: This long-term analysis identified several late toxicities not evident during standard follow-up, no local failures beyond 10 years, and no radiation-induced secondary malignancies. Although limited by the small sample size and survivorship bias, these findings underscore the importance of extended surveillance and provide insight into the very late effects of SBRT.
引用
- Matsuda M, Komiyama T, Marino K, et al. Evaluation of cases with over 10 years of follow-up after stereotactic body radiotherapy for Stage I lung cancer. Pract Radiat Oncol. 2026. PMID: 42810616. doi:10.1016/j.prro.2026.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。